The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2024 | Akkermansia muciniphila as a biomarker for ICI response in NSCLC
Lorenzo Belluomini, PhD, University of Verona, Verona, Italy, discusses findings from a study (NCT04567446) assessing the role of Akkermansia muciniphila (Akk) abundance as a biomarker for immune checkpoint inhibitor (ICI) response in advanced non-small cell lung cancer (NSCLC). Stool and blood samples from patients receiving ICI with or without chemotherapy were analyzed. Patients with lower Akk levels showed improved progression-free survival (PFS) compared to those with higher or absent Akk levels. Anti-Akk IgG and T cell responses also correlated with worse outcomes, suggesting Akk modulation as a potential strategy to improve ICI efficacy. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
